2013-09-05 14:11:15 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Henan Lingrui Pharmaceutical Co., Ltd. (600285) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Henan Lingrui Pharmaceutical Co., Ltd. (600285). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Henan Lingrui Pharmaceutical Co., Ltd. investor.
Report Summary: Henan Lingrui Pharmaceutical Co., Ltd. is a below average quality company with a neutral outlook. Henan Lingrui Pharmaceutical Co., Ltd. has weak business growth and is run by efficient management. The trend in Henan Lingrui Pharmaceutical Co., Ltd. fair value exchange rate against its closest rated-competitor, Shanghai Modern Pharmaceutical Co., Ltd., has been stable over the past 2 weeks. When compared to its closest competitor, Henan Lingrui Pharmaceutical Co., Ltd. shows similar overvaluation and is
equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Henan Lingrui Pharmaceutical Co., Ltd. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.